(MedPage Today) — LAS VEGAS — GLP-1-based therapies may offer benefits in inflammatory bowel disease (IBD) that extend beyond their metabolic indication, according to two poster presentations at the Crohn’s & Colitis Congress.
In a large…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
